TY - JOUR
T1 - Proteomic analysis of circulating extracellular vesicles identifies potential markers of breast cancer progression, recurrence, and response
AU - Vinik, Yaron
AU - Ortega, Francisco Gabriel
AU - Mills, Gordon B.
AU - Lu, Yilling
AU - Jurkowicz, Menucha
AU - Halperin, Sharon
AU - Aharoni, Mor
AU - Gutman, Mordechai
AU - Lev, Sima
N1 - Publisher Copyright:
© 2020 The Authors, some rights reserved; exclusive licensee American Association for the Advancement of Science. No claim to original U.S. Government Works. Distributed under a Creative Commons Attribution NonCommercial License 4.0 (CC BY-NC).
PY - 2020/9/30
Y1 - 2020/9/30
N2 - Proteomic profiling of circulating small extracellular vesicles (sEVs) represents a promising, noninvasive approach for early detection and therapeutic monitoring of breast cancer (BC). We describe a relatively low-cost, fast, and reliable method to isolate sEVs from plasma of BC patients and analyze their protein content by semiquantitative proteomics. sEV-enriched fractions were isolated from plasma of healthy controls and BC patients at different disease stages before and after surgery. Proteomic analysis of sEV-enriched fractions using reverse phase protein array revealed a signature of seven proteins that differentiated BC patients from healthy individuals, of which FAK and fibronectin displayed high diagnostic accuracy. The size of sEVs was significantly reduced in advanced disease stage, concomitant with a stage-specific protein signature. Furthermore, we observed protein-based distinct clusters of healthy controls, chemotherapy-treated and untreated postsurgery samples, as well as a predictor of high risk of cancer relapse, suggesting that the applied methods warrant development for advanced diagnostics.
AB - Proteomic profiling of circulating small extracellular vesicles (sEVs) represents a promising, noninvasive approach for early detection and therapeutic monitoring of breast cancer (BC). We describe a relatively low-cost, fast, and reliable method to isolate sEVs from plasma of BC patients and analyze their protein content by semiquantitative proteomics. sEV-enriched fractions were isolated from plasma of healthy controls and BC patients at different disease stages before and after surgery. Proteomic analysis of sEV-enriched fractions using reverse phase protein array revealed a signature of seven proteins that differentiated BC patients from healthy individuals, of which FAK and fibronectin displayed high diagnostic accuracy. The size of sEVs was significantly reduced in advanced disease stage, concomitant with a stage-specific protein signature. Furthermore, we observed protein-based distinct clusters of healthy controls, chemotherapy-treated and untreated postsurgery samples, as well as a predictor of high risk of cancer relapse, suggesting that the applied methods warrant development for advanced diagnostics.
UR - http://www.scopus.com/inward/record.url?scp=85092679563&partnerID=8YFLogxK
U2 - 10.1126/sciadv.aba5714
DO - 10.1126/sciadv.aba5714
M3 - ???researchoutput.researchoutputtypes.contributiontojournal.article???
C2 - 33008904
AN - SCOPUS:85092679563
SN - 2375-2548
VL - 6
JO - Science advances
JF - Science advances
IS - 40
M1 - eaba5714
ER -